Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:HELP NASDAQ:PGEN NASDAQ:STOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$81.92+1.4%$81.47$62.60▼$99.50$1.84B0.43383,943 shs242,739 shsHELPCybin$7.04+8.1%$5.13$3.76▼$9.12$491.89M0.621.02 million shs3.78 million shsPGENPrecigen$4.95-3.3%$4.69$1.47▼$6.04$1.76B14.51 million shs3.94 million shsSTOKStoke Therapeutics$29.11-2.7%$30.83$11.89▼$40.22$1.81B1.17746,248 shs555,053 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.34%-4.66%-1.79%+3.52%+26.28%HELPCybin-2.54%+4.49%+53.18%+18.36%+650,999,900.00%PGENPrecigen0.00%-7.91%+6.67%+29.62%+176.76%STOKStoke Therapeutics+2.68%-8.39%-0.30%-15.37%+154.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$81.92+1.4%$81.47$62.60▼$99.50$1.84B0.43383,943 shs242,739 shsHELPCybin$7.04+8.1%$5.13$3.76▼$9.12$491.89M0.621.02 million shs3.78 million shsPGENPrecigen$4.95-3.3%$4.69$1.47▼$6.04$1.76B14.51 million shs3.94 million shsSTOKStoke Therapeutics$29.11-2.7%$30.83$11.89▼$40.22$1.81B1.17746,248 shs555,053 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.34%-4.66%-1.79%+3.52%+26.28%HELPCybin-2.54%+4.49%+53.18%+18.36%+650,999,900.00%PGENPrecigen0.00%-7.91%+6.67%+29.62%+176.76%STOKStoke Therapeutics+2.68%-8.39%-0.30%-15.37%+154.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 2.75Moderate Buy$107.3331.02% UpsideHELPCybin 3.00Buy$55.00681.25% UpsidePGENPrecigen 2.33Hold$12.50152.53% UpsideSTOKStoke Therapeutics 2.75Moderate Buy$42.0044.28% UpsideCurrent Analyst Ratings BreakdownLatest HELP, ANIP, PGEN, and STOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/13/2026STOKStoke Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.007/13/2026STOKStoke Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.007/10/2026ANIPANI Pharmaceuticals GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$124.006/23/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C+) ➝ Buy (B-)6/1/2026ANIPANI Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C+)5/28/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.005/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.005/14/2026PGENPrecigen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026ANIPANI Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/14/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $11.005/11/2026STOKStoke Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)(Data available from 7/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$923.71M2.02$10.10 per share8.11$24.03 per share3.41HELPCybinN/AN/AN/AN/A$4.49 per shareN/APGENPrecigen$9.68M182.31N/AN/A$0.06 per share82.50STOKStoke Therapeutics$184.42M9.83N/AN/A$6.17 per share4.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals$78.34M$3.9520.749.46N/A9.98%27.51%10.02%8/14/2026 (Estimated)HELPCybin-$148M-$4.23N/AN/AN/AN/A-68.27%-58.26%N/APGENPrecigen-$250.64M-$1.18N/A19.80N/A-646.99%717.50%58.48%8/11/2026 (Estimated)STOKStoke Therapeutics-$6.89M-$2.81N/AN/AN/A-529.20%-48.84%-42.27%8/11/2026 (Estimated)Latest HELP, ANIP, PGEN, and STOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026PGENPrecigen-$0.02N/AN/AN/A$27.98 millionN/A8/11/2026Q2 2026STOKStoke Therapeutics-$0.82N/AN/AN/A$4.89 millionN/A5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million5/8/2026Q1 2026ANIPANI Pharmaceuticals$1.28$2.05+$0.77$1.28$207.63 million$237.46 million5/7/2026Q1 2026STOKStoke Therapeutics-$0.80-$0.79+$0.01-$0.79$6.48 million$6.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AHELPCybinN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ASTOKStoke TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.063.122.52HELPCybinN/A9.529.52PGENPrecigen4.624.824.12STOKStoke TherapeuticsN/A8.998.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%HELPCybin17.94%PGENPrecigen33.51%STOKStoke TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals8.10%HELPCybin15.00%PGENPrecigen41.40%STOKStoke Therapeutics9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60022.75 million20.90 millionOptionableHELPCybin5069.87 million58.65 millionN/APGENPrecigen190356.51 million208.92 millionOptionableSTOKStoke Therapeutics10062.28 million56.30 millionOptionableHELP, ANIP, PGEN, and STOK HeadlinesRecent News About These CompaniesStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)2 hours ago | businesswire.comStoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs GroupJuly 14 at 7:35 AM | marketbeat.comStoke Tx appoints Thomas McCauley as CSOJuly 13 at 10:10 AM | thepharmaletter.comTStoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific OfficerJuly 13 at 10:10 AM | finance.yahoo.comCandriam S.C.A. Has $16.35 Million Stake in Stoke Therapeutics, Inc. $STOKJuly 12, 2026 | marketbeat.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 10, 2026 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 10, 2026 | marketbeat.comMoran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOKJuly 7, 2026 | marketbeat.comStoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet ...June 30, 2026 | finance.yahoo.comAssenagon Asset Management S.A. Sells 320,708 Shares of Stoke Therapeutics, Inc. $STOKJune 27, 2026 | marketbeat.comJonathan Allan Sells 1,457 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 19, 2026 | insidertrades.comGranahan Investment Management LLC Has $6.08 Million Stock Position in Stoke Therapeutics, Inc. $STOKJune 17, 2026 | marketbeat.comStoke Therapeutics, Inc. (STOK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 8, 2026 | seekingalpha.com4 Biotech Stocks Investors Should Watch in 2026June 5, 2026 | zacks.comStoke Therapeutics Stockholders Approve Directors and Governance ItemsJune 4, 2026 | tipranks.comStoke Therapeutics (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?June 4, 2026 | zacks.comBarry Ticho Sells 1,795 Shares of Stoke Therapeutics (NASDAQ:STOK) StockJune 4, 2026 | insidertrades.comStoke Therapeutics, Inc. (STOK) Reports Q1 Results and Business UpdatesJune 1, 2026 | insidermonkey.comStoke Therapeutics to Present at Upcoming Investor Conferences in JuneMay 29, 2026 | finance.yahoo.comIs it a Good Idea to Invest in Stoke Therapeutics Stock Now?May 21, 2026 | zacks.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)May 18, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines5 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026The Oil Trade May Not Be Over: 3 Energy Stocks to WatchBy Thomas Hughes | June 21, 20263 Inflation-Fighting Stocks Built for Higher Oil PricesBy Thomas Hughes | June 21, 20263 Rare-Earth ETFs That Help Investors Balance Exposure and RiskBy Chris Markoch | July 12, 2026Beyond the AI Trade: 3 Defensive Stocks Built for StabilityBy Thomas Hughes | June 20, 2026HELP, ANIP, PGEN, and STOK Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$81.92 +1.10 (+1.36%) Closing price 04:00 PM EasternExtended Trading$81.37 -0.55 (-0.67%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Cybin NASDAQ:HELP$7.04 +0.53 (+8.14%) Closing price 04:00 PM EasternExtended Trading$7.10 +0.05 (+0.78%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a discovery-phase phenethylamine derivative to treat neuroinflammation and psychiatric conditions. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Precigen NASDAQ:PGEN$4.95 -0.17 (-3.32%) Closing price 04:00 PM EasternExtended Trading$4.97 +0.02 (+0.40%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.Stoke Therapeutics NASDAQ:STOK$29.11 -0.80 (-2.67%) Closing price 04:00 PM EasternExtended Trading$29.12 +0.02 (+0.05%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Revving Up Returns: Big Banks Race Through the Rate Plateau Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase Japan’s Crypto Overhaul Could Open the Door to a Wave of Institutional Money AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks PayPal Stock Surges on $53 Billion Stripe-Advent Buyout Bid Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
